Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for cancer. Due to the mechanism of action of ICIs, inflammatory reactions against normal tissue were an anticipated side effect of these agents; these immune‐related adverse events have been documented and are typically lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Neilan, Tomas G., Rothenberg, Mace L., Amiri‐Kordestani, Laleh, Sullivan, Ryan J., Steingart, Richard M., Gregory, William, Hariharan, Subramanian, Hammad, Tarek A., Lindenfeld, JoAnn, Murphy, Martin J., Moslehi, Javid J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156187/
https://www.ncbi.nlm.nih.gov/pubmed/29802220
http://dx.doi.org/10.1634/theoncologist.2018-0157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156187/
https://www.ncbi.nlm.nih.gov/pubmed/29802220
http://dx.doi.org/10.1634/theoncologist.2018-0157

Ejemplares similares